Patents Assigned to Stichting Rega VZW (REGA)
  • Publication number: 20070031409
    Abstract: A method for producing biologically active Fv antibody fragments that have a neutralizing effect on the anti-viral activity of human interferon-gamma (IFN-?) by inserting an isolated nucleic acid, having nucleotide sequences that encode the VH and VL domains of the D9D10 monoclonal antibody and a nucleotide sequence that encodes a linker peptide which links the VH and VL domains, into a suitable expression vector, in order to encode FV antibody fragments. Such Fv antibody fragments can be used to treat human diseases, such as endotoxic shock, local inflammation, cerebral malaria, and autoimmune arthritis.
    Type: Application
    Filed: February 11, 2005
    Publication date: February 8, 2007
    Applicant: Stichting Rega VZW
    Inventors: Alfons Billiau, Guido Froyen
  • Patent number: 5840524
    Abstract: This invention is directed to a new family of mammalian chemokine proteins, which have been designated granulocyte chemotactic protein-2 (GCP-2) proteins, and includes mammalian GCP-2, sequence-related variants of mammalian GCP-2, and distinct peptide fragments of GCP-2.
    Type: Grant
    Filed: May 24, 1995
    Date of Patent: November 24, 1998
    Assignee: Stichting Rega vzw
    Inventors: Jo Van Damme, Paul Proost
  • Patent number: 5668113
    Abstract: It has been found that 1,5-anhydrohexitol nucleoside analogues, wherein a 4-substituted-2,3,4-trideoxy-1,5-anhydrohexitol is coupled via its 2-position to the heterocyclic ring of a pyrimidine or purine base, exhibit remarkable anti-viral properties against herpes viruses, pox viruses and related viruses.The new nucleoside analogues are represented by the general formula I ##STR1## wherein B is a heterocyclic ring derived from a pyrimidine or purine base, X represents H, N.sub.3, F, Cl, Br, I, amino, --NHR.sup.2, --N(R.sup.2).sub.2, --OR.sup.2, --SR.sup.2 or CN, R.sup.1 and R.sup.2 are the same or different and hydrogen, alkyl, acyl or phosphate groups are represented, or wherein X is hydrogen and a double bond is situated between the 3- and 4- position of the 1,5-anhydrohexitol ring.Pharmaceutically acceptable salts and esters thereof are included.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: September 16, 1997
    Assignee: Stichting Rega VZW
    Inventors: Erik Desire Alice De Clercq, Piet Andre Maurits Herdewlin, Arthur Albert Edgard Van Aerschot
  • Patent number: 5607922
    Abstract: 1,5-Anhydrohexitol nucleoside analogues represented by the general formula I: ##STR1## wherein the hexitol has the D-configuration and the carbon atom on which the base moiety and the X substituent stand both have the (S)-configuration and further wherein:B is a heterocyclic ring selected from the group consisting of pyrimidine and purine bases; andX is hydrogen, azido, F, Cl, Br, I, amino, --NHR.sup.2, --N(R.sup.2).sub.2, --OR.sup.2, --SR.sup.2, or CN; wherein R.sup.1 and R.sup.2 are the same or different and are selected from the group consisting of hydrogen, substituted or unsubstituted C.sub.1 -C.sub.20 alkyl, substituted or unsubstituted C.sub.1 -C.sub.20 alkenyl, aroyl, C.sub.1 -C.sub.20 alkanoyl, and phosphoryl.These nucleoside analogues are useful as antiviral agents against herpes simplex virus, vaccina virus, or varicella zoster virus. The definition of the X group should include --N(R.sup.2).sub.2 instead of --N(N.sup.2).sub.2.
    Type: Grant
    Filed: December 17, 1993
    Date of Patent: March 4, 1997
    Assignee: Stichting Rega VZW
    Inventors: Erik D. A. De Clercq, Piet A. M. Herdewijn, Arthur A. E. Van Aerschot
  • Patent number: 5292505
    Abstract: Sulphated vinyl polymers such as sulphated polyvinylalcohol, sulphated copolymers of (meth)acrylic acid and vinylalcohol, and pharmaceutically acceptable salts thereof, have an antiviral effect against human immunodeficiency virus and may therefore be used as a therapeutic agent for treating retrovirus infections like AIDS and AIDS-related diseases. Their antiviral activity is apparently based on inhibition of virus adsorption; their inhibitory effect on giant cell formation is stronger than that of dextran sulphate.
    Type: Grant
    Filed: January 15, 1992
    Date of Patent: March 8, 1994
    Assignees: Stichting Rega VZW, Richter Gedeon Vegyeszeti Gyar RT
    Inventors: Masanori Baba, Erik D. A. De Clercq, Sandor Gorog, Miklos Low, Miklos Nagy, Sandorne Gyorgyi
  • Patent number: 5152978
    Abstract: Sulphated vinyl polymers such as sulphated polyvinylalcohol, sulphated copolymers of (meth)acrylic acid and vinylalcohol, and pharmaceutically acceptable salts thereof, have an antiviral effect against human immunodeficiency virus and may therefore be used as a therapeutic agent for treating retrovirus infections like AIDS and AIDS-related diseases. Their antiviral activity is apparently based on inhibition of virus adsorption; their inhibitory effect on giant cell formation is stronger than that of dextran sulphate.
    Type: Grant
    Filed: February 23, 1989
    Date of Patent: October 6, 1992
    Assignees: Stichting Rega VZW, Richter Gedeon Vegyeszeti Gyar R.T.
    Inventors: Masanori Baba, Erik D. A. De Clercq, Sandor Gorog, Miklos Low, Miklos Nagy, Sandorne Gyorgyi
  • Patent number: 5137724
    Abstract: The antiviral activity of 5-fluoro-uracil, 5-fluoro-2'-deoxyuridine and similar thymilydate synthetase inhibitors towards herpes viruses can be potentiated dramatically by combining these compounds with compounds having viral thymidine kinase inhibiting activity.
    Type: Grant
    Filed: July 22, 1991
    Date of Patent: August 11, 1992
    Assignee: Stichting Rega VZW
    Inventors: Jan M. R. Balzarini, Erik D. A. De Clercq
  • Patent number: 5116822
    Abstract: The compound 2',3'-dideoxycytidinene has an antiviral effect against human immunodeficiency virus (HIV) and may therefore be used as a therapeutic agent for treating AIDS and related diseases.
    Type: Grant
    Filed: July 2, 1990
    Date of Patent: May 26, 1992
    Assignees: Stichting Rega VZW, The United States of America as represented by the Department of Health and Human Serices
    Inventors: Erik D. A. De Clercq, Piet A. M. M. Herdewijn, Samuel Broder, Jan M. R. Balzarini
  • Patent number: 4988678
    Abstract: The antitumor activity of 5-fluorouracil and its precursors against adenocarcinomas can be potentiated without a corresponding increase in toxicity by combining these compounds with (E)-5-(2-bromovinyl)-uracil or a precursor thereof. The combinations may have the form of a single composition or two separate compositions.
    Type: Grant
    Filed: June 29, 1989
    Date of Patent: January 29, 1991
    Assignee: Stichting Rega VZW
    Inventors: Erik De Clercq, Masaaki Iigo
  • Patent number: 4963533
    Abstract: The present invention relates to a composition containing the compound 2', 3'-dideoxycytidinene which has an antiviral effect against human immunodeficiency virus (HIV) and may therefore be used as a therapeutic agent for the treatment of AIDS and AIDS related diseases.
    Type: Grant
    Filed: October 24, 1986
    Date of Patent: October 16, 1990
    Assignees: Stichting Rega VZW (REGA), The Government of the United States of America
    Inventors: Erik D. A. de Clercq, Piet A. M. M. Herdewijn, Samuel Broder, Jan M. R. Balzarini
  • Patent number: 4894365
    Abstract: The antitumor activity of 5-fluorouracil and its precursors against adenocarcinomas can be potentiated without a corresponding increase in toxicity by combining these compounds with (E)-5-(2-bromovinyl)-uracil or a precursor thereof. The combinations may have the form of a single composition or two separate compositions.
    Type: Grant
    Filed: February 11, 1988
    Date of Patent: January 16, 1990
    Assignee: Stichting Rega VZW
    Inventors: Erik De Clercq, Masaaki Iigo
  • Patent number: 4724233
    Abstract: The (S) and (RS) forms of certain phosphonylmethoxyalkyl adenines and their salts have an antiviral effect against several DNA viruses and can be used for the treatment of virus diseases in human and veterinary medicine.
    Type: Grant
    Filed: April 21, 1986
    Date of Patent: February 9, 1988
    Assignees: Stichting Rega VZW, Ceskoslovenska Akademie VED
    Inventors: Erik De Clercq, Antonin Holy, Ivan Rosenberg
  • Patent number: 4605658
    Abstract: Certain esters of 3-(adenin-9-yl)-2-hydroxypropanoic acid are disclosed which exhibit an improved broad spectrum antiviral activity while having a low toxicity for living cells. They can be used for treatment of virus diseases in human and veterinary practice.
    Type: Grant
    Filed: October 5, 1984
    Date of Patent: August 12, 1986
    Assignees: Ceskoslovenska Akademie Ved., Stichting Rega VZW
    Inventors: Antonin Holy, Erik de Clercq